Here are some Quotes from the FAX BULLETIN that Maedel's group issued on Nortran Pharmaceuticals (NRT:VSE) on friday.
Maedel's MINI-CAP ANALYST:
BIOTECH BLOCKBUSTER: NORTRAN PHARMACEUTICALS INC.
Vancouver Stock Exchange:NRT $0.97 Very strong buy-expect immediate appreciation
Nortran's scientists have targeted two behemoth drug applications, heart attacks and pain, which are multi-billion dollar markets, and are applying their world-class knowledge to create novel ion channel drugs that have shown promising results in pre-clinical and clinical testing.
"In share price terms, this equates to a share price of $3.78 on a fully diluted basis. In the long term, of course, we expect Nortran's shares to trend dramatically higher fiven that the key milestones of establishing strategic alliances and successful clinical trial results are achieved."
"Nortran's primary focus has been life-threatening arrhythmias(abnormal electrical signals) due to heart attacks."
"While today's drugs to control arrhythmias due to heart attacks are intended for acute use, i.e. they are administered during and shortly after a heart attack, Nortran's 'ideal' drug will serve as a prophylactic or preventative agent-"one a day" for all people predisposed to heart attacks, with a market potential of US $16 billion."
"Nortran's second generation drug will function as an acute and chronic treatment. This is a blockbuster-potential drug, offering the promise of being significantly more effective with drematically reduced side effects relative to current drugs, with a market opportunity of roughly US $2 billion to $4 billion.
"Nortran's second area of focus is pain, or as they put it, intractable pain. Drugs to relieve pain, called analgesics, today represent a worldwide market worth US $10 billion. Nortran secured the rights to a class of compounds,called nocieptor blockers, that show tremendous promise for more specifically targeting areas of pain and providing longer-lasting relief while also reducing the serious toxicity and detrimental side effects of today's existing agents. One of these compounds has already been through Phase 1 for another indication(application) and we expect to see Nortran enter Phase 1/11 clinical trials for the pain application in 1997. Nortran's first group of drugs in this class will target a portion of the market valued at US $1 billion."
"Behind this emerging drug discovery company is an impressive set of credentials. In the scientific community, lead innovator and scientist Dr. Michael Walker is internationally recognized and respected for his unique application of ion channel blocking to arrhythmias. Dr. David Quastel is also recognized for his ion chsnnel research applied to pain-killing. Nortran's Board of Directors includes experienced management talent in Mr. Gordon Politeski, who has more that 25 years' experience in the pharmaceutical industry. Mr. Politeski was president and CEO of Biomira Inc., one of Canada's largest biotechnology companies, and prior to that was president of Allergan Pharmaceuticals. Mr. Colin Mallet was president and CEO of Sandoz Canada. Dr. Clive Page is a professor at Kings College, University of London, UK and is a world expert in asthma and other inflammatory diseases. Dr. Allen Bain, who is also an expert on ion channel pharmacology, is also a director and is currently the President of Nortran."
"With $3.2 million in the bank (post-financing) and the high probability of another $2 million being realized through converted warrents over the next few months, Nortran can now also inplement another element of its growth plans"
"Wrap this all up with a complete lack of recognition by the financial market, and we end up with an undervalued situation and an excellent opportunity for our subscribers to realize tremendous capital gains. It's a buy."
*Note I have re-typed clipping from the Fax bulletin highlighting some of the interesting points.
** Note ** to obtain a copy of the full Fax Bulletin contact Maedel's Mini-Cap Analyst: 604-669-8270 or via fax: 604-683-5610
Nortran's web site is at: www.nortran.com or call them directly at: 604-822-2278
or at: 1-800-330-9928
Here's to a profitable week!
Mike Leonard |
